Advances in cellular and humoral immunotherapy – implications for the treatment of poor risk childhood, adolescent, and young adult B‐cell non‐Hodgkin lymphoma

Summary Patients with relapsed, refractory or advanced stage B non‐Hodgkin lymphoma (NHL) continue to have a dismal prognosis. This review summarises current and novel cellular and immunotherapy for these high‐risk populations, including haematopoietic stem cell transplant, bispecific antibodies, vi...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	British journal of haematology 2019-06, Vol.185 (6), p.1055-1070
Hauptverfasser:	Chu, Yaya, Gardenswartz, Aliza, Termuhlen, Amanda M., Cairo, Mitchell S.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Age Factors Animals Bispecific antibodies B‐cell non‐Hodgkin lymphoma cellular immunotherapy Child Child, Preschool Children chimeric antigen receptor Chimeric antigen receptors Combined Modality Therapy - adverse effects Combined Modality Therapy - methods Cytotoxicity Disease Management Hematology Hematopoietic stem cells Humans IL‐15 superagonist Immunity, Cellular Immunity, Humoral Immunotherapy Immunotherapy - adverse effects Immunotherapy - methods Lymphocytes Lymphocytes B Lymphocytes T Lymphoma Lymphoma, B-Cell - immunology Lymphoma, B-Cell - metabolism Lymphoma, B-Cell - therapy Lymphoma, Non-Hodgkin - immunology Lymphoma, Non-Hodgkin - metabolism Lymphoma, Non-Hodgkin - therapy Natural killer cells Non-Hodgkin's lymphoma stem cell transplantation Young Adult Young adults
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Summary Patients with relapsed, refractory or advanced stage B non‐Hodgkin lymphoma (NHL) continue to have a dismal prognosis. This review summarises current and novel cellular and immunotherapy for these high‐risk populations, including haematopoietic stem cell transplant, bispecific antibodies, viral‐derived cytotoxic T cells, chimeric antigen receptor (CAR) T cells, and natural killer (NK) cell therapy, as discussed at the 6th International Symposium on Childhood, Adolescent and Young Adult Non‐Hodgkin Lymphoma on September 26th–29th 2018 in Rotterdam, the Netherlands, and explores the future of NK/CAR NK therapies.
ISSN:	0007-1048 1365-2141
DOI:	10.1111/bjh.15753